维生素D受体 (VDR) 多态性和骨科患者的心脏代谢特征:基于集群的分析
Dariusz Larysz1, Remigiusz Recław2,3, Aleksandra Suchanecka2
1Department of Trauma and Orthopaedic Surgery, 109th Military Hospital with Polyclinic, Ministry of National Defense, ul. Ksiedza Piotra Skargi 9/11, 71-422 Szczecin, Poland.
International journal of molecular sciences
|February 27, 2026
概括
遗传变异影响心脏代谢风险和生活质量. 这项研究使用聚类来识别患者子组,揭示了与骨科患者特定基因多态性相关的独特心脏代谢特征.
科学领域:
- 遗传学和精准医学 遗传学和精准医学
- 心血管和新陈代谢健康
- 整形外科手术的结果
背景情况:
- 心脏代谢风险和生活质量的个体变异性受到遗传多态化的影响.
- 这些遗传因素的临床相关性往往被人口异质性和单变体分析所掩盖.
- 整形外科患者经常经历心脏代谢性并发症,突出显示了综合遗传和表型见解的必要性.
研究的目的:
- 通过整合遗传和表型数据,对骨科患者的复杂疾病概况进行表征.
- 通过基于临床,人体测量,血液学,生化和生活质量数据的无监督聚类来确定同质的患者子组.
- 研究特定基因多态 (VDR,COMT,OPRM1) 与已识别的患者群的关联.
主要方法:
- 在维生素D受体 (VDR),catechol-O-methyltransferase (COMT rs4680) 和阿片类受体mu 1 (OPRM1 rs510769) 基因中的多态性基因的基因定型.
- 收集了289名骨科手术患者的综合临床,人体测量,血液学,生化和SF-36生活质量数据.
- 应用无监督的k-means集群来识别患者子组,然后进行ANOVA和奇平方测试来评估集群间的差异.
主要成果:
- 确定了三个不同的患者群,每个患者的特点是心脏代谢,炎症和生活质量特征的独特组合.
- VDR多态表现出跨集群的差异分布,与体重指数,高血压患病率和炎症状况的变化相关.
- COMT和OPRM1变异与身体和精神生活质量维度的差异有关,强调了多维临床异质性.
结论:
- 基于集群的方法有效地揭示了心脏代谢概况中的复杂患者异质性,超过了传统的单变量分析.
- 将遗传多态度与临床和生活质量数据相结合,有助于识别和解释骨科群体内不同心脏代谢特征.
- 这种分层框架支持精准导向的研究,用于骨科和心脏代谢患者管理.
相关概念视频
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54
01:27Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
01:11Genome-wide Association Studies-GWAS
16.0K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.0K
01:27Principles of Pharmacogenetics: Types of Genetic Variants
59
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
59